Domenic A Sica

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi request reprint Endocrine causes of secondary hypertension
    Domenic A Sica
    Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 10:534-40. 2008
  2. doi request reprint Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study
    Domenic Sica
    Division of Nephrology, Department of Medicine and Pharmacology, Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 14:284-92. 2012
  3. doi request reprint Edema mechanisms in the patient with heart failure and treatment options
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    Heart Fail Clin 4:511-8. 2008
  4. doi request reprint The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Sanger Hall, Room 8 062, Richmond, VA 23298 0160, USA
    Curr Hypertens Rep 12:67-73. 2010
  5. doi request reprint Management of hypertension in the outpatient setting
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, 1101 East Marshall Street, Sanger Hall, Room 8 062, Richmond, VA 23298 0160, USA
    Prim Care 35:451-73, vi. 2008
  6. ncbi request reprint Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Curr Hypertens Rep 10:330-5. 2008
  7. ncbi request reprint The kidney and hypertension: causes and treatment
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 10:541-8. 2008
  8. ncbi request reprint Loop diuretic therapy, thiamine balance, and heart failure
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 13:244-7. 2007
  9. ncbi request reprint Considerations in drug handling in renal disease
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Clin Pharmacokinet 46:677-9. 2007
  10. ncbi request reprint Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?
    Domenic A Sica
    Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Curr Hypertens Rep 10:415-20. 2008

Detail Information

Publications101 found, 100 shown here

  1. ncbi request reprint Endocrine causes of secondary hypertension
    Domenic A Sica
    Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 10:534-40. 2008
    ..It is important to identify secondary causes of hypertension that are endocrine in nature because surgical intervention may result in correction or substantial improvement of the hypertension...
  2. doi request reprint Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study
    Domenic Sica
    Division of Nephrology, Department of Medicine and Pharmacology, Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 14:284-92. 2012
    ..In patients with stage 2 hypertension, treatment with the combination of AZL-M and CLD resulted in substantially greater SBP reduction compared with either agent alone...
  3. doi request reprint Edema mechanisms in the patient with heart failure and treatment options
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    Heart Fail Clin 4:511-8. 2008
    ..In heart failure, diuretics should always be given in the lowest possible dose with careful attention to reducing dietary sodium intake...
  4. doi request reprint The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Sanger Hall, Room 8 062, Richmond, VA 23298 0160, USA
    Curr Hypertens Rep 12:67-73. 2010
    ....
  5. doi request reprint Management of hypertension in the outpatient setting
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, 1101 East Marshall Street, Sanger Hall, Room 8 062, Richmond, VA 23298 0160, USA
    Prim Care 35:451-73, vi. 2008
    ..As blood pressure is brought to goal in the patient with hypertension, ongoing attention should be directed to long-term adherence to therapy...
  6. ncbi request reprint Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Curr Hypertens Rep 10:330-5. 2008
    ..The most recently introduced drugs, the vasodilating beta-blockers carvedilol and nebivolol, are now being broadly evaluated as to their efficacy and tolerability in clinical practice...
  7. ncbi request reprint The kidney and hypertension: causes and treatment
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 10:541-8. 2008
    ..It remains to be determined to what level blood pressure should be lowered in the patient with chronic kidney disease, however...
  8. ncbi request reprint Loop diuretic therapy, thiamine balance, and heart failure
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 13:244-7. 2007
    ..The role of thiamine in heart failure, however, remains arguable...
  9. ncbi request reprint Considerations in drug handling in renal disease
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Clin Pharmacokinet 46:677-9. 2007
  10. ncbi request reprint Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?
    Domenic A Sica
    Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Curr Hypertens Rep 10:415-20. 2008
    ....
  11. ncbi request reprint Fibrate therapy and renal function
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Sanger Hall, Room 8 062, Richmond, VA 23298 0160, USA
    Curr Atheroscler Rep 11:338-42. 2009
    ..Serum creatinine values can take several weeks to return to their baseline values following discontinuation of a fibrate...
  12. doi request reprint Diuretic use in renal disease
    Domenic A Sica
    Virginia Commonwealth University Health System, 1101 East Marshall Street, Sanger Hall, Room 8 062, Richmond, VA 23298 0160, USA
    Nat Rev Nephrol 8:100-9. 2012
    ..As a result of diuretic-related adverse events, clinicians must be resourceful in the dose amount and frequency of dosing...
  13. doi request reprint What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
    Domenic A Sica
    Medicine and Pharmacology, Clinical Pharmacology and Hypertension, Richmond, USA
    Curr Cardiol Rep 13:520-6. 2011
    ..As such, steps should be taken to lessen the likelihood of it occurring if therapy is being contemplated with agents in this class...
  14. doi request reprint Thiazide and loop diuretics
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, MCV Station, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 13:639-43. 2011
    ....
  15. doi request reprint Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 13:467-72. 2011
    ..These findings suggest that AZL-M could provide higher rates of hypertension control compared with other ARBs in the class...
  16. doi request reprint Are there pleiotropic effects of antihypertensive medications or is it all about the blood pressure in the patient with diabetes and hypertension?
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 13:301-4. 2011
    ..In the patient with diabetes and hypertension, tight blood pressure control, more so than using a specific drug class, is the most important aspect of therapy...
  17. doi request reprint Pharmacologic Issues in treating hypertension in CKD
    Domenic A Sica
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    Adv Chronic Kidney Dis 18:42-7. 2011
    ..This article will review the various classes of antihypertensive drugs used in the management of high BP in patients with CKD, with an emphasis on pitfalls that arise when kidney function is impaired...
  18. doi request reprint Can focused US with a diagnostic US contrast agent favorably affect renal function?
    Domenic A Sica
    Division of Nephrology, Virginia Commonwealth University Health System, Box 980160, MCV Station, Richmond, VA 23298 0160, USA
    Radiology 253:577-8. 2009
    ..In its current form, this process has very limited application potential to states of abnormal renal function...
  19. ncbi request reprint Hypertension, renal disease, and drug considerations
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:24-30. 2004
    ..A number of questions still remain unanswered in the pharmacotherapy of chronic kidney disease, including the optimal dose for these drugs as well as what represents the most favorable achieved blood pressure...
  20. doi request reprint Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension
    Maria M Ng
    Department of Medicine, Ronald Reagan UCLA Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Cardiol Rev 19:52-7. 2011
    ..Clinical trials designed to evaluate the efficacy and safety of this therapy in patients with treatment resistant hypertension, are now ongoing in both Europe and the United States...
  21. ncbi request reprint Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:414-20. 2003
    ..Additional clarifying studies are required to establish whether specific patient subsets exist that might benefit from such combination therapy...
  22. ncbi request reprint Antihypertensive therapy and its effects on potassium homeostasis
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 8:67-73. 2006
    ..Guidelines for the monitoring of serum potassium levels in the setting of antihypertensive therapy are at best makeshift and often drawn from the know-how of the treating physician...
  23. ncbi request reprint Aldosterone-receptor antagonism and end-stage renal disease
    Niall McLaughlin
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Box 980160, Richmond, VA 23298, USA
    Curr Hypertens Rep 6:327-30. 2004
    ..Eplerenone has not been studied in ESRD in a therapeutic or safety capacity. Additional studies are needed with these compounds in the ESRD population before their use can be considered safe...
  24. ncbi request reprint Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Box 980160, MCV Station, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 7:59-64. 2005
  25. ncbi request reprint Angiotensin receptor blockers: new considerations in their mechanism of action
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 8:381-5. 2006
    ..As the mechanistic basis for the action(s) of angiotensin receptor blockers more completely unfolds, added credence may ultimately be lent to widely touted and often overstated intraclass differences...
  26. ncbi request reprint ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials
    Domenic A Sica
    Virginia Commonwealth University, MCV Station Box 980160, Richmond, VA 23298 0160, USA
    Congest Heart Fail 10:160-4. 2004
    ....
  27. ncbi request reprint Are current strategies for treating hypertension effective?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:23-32. 2003
    ....
  28. ncbi request reprint Clinical pharmacokinetics of losartan
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, PO Box 980160, Richmond, VA 23298, USA
    Clin Pharmacokinet 44:797-814. 2005
    ..Losartan, like other angiotensin-receptor antagonists, is devoid of significant adverse effects...
  29. ncbi request reprint Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 10:259-64. 2004
    ..The frequency of such scrutiny should be patient-specific and based on the constellation of risk factors for hyperkalemia...
  30. ncbi request reprint Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 8:334-41, 345. 2002
    ..The need to reduce renin-angiotensin aldosterone system activity in a heart failure patient would seem to justify the small risk of angioedema with ARB therapy in a patient having previously experienced ACE inhibitor-related angioedema...
  31. pmc Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats
    Siddhartha S Ghosh
    Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
    Am J Physiol Heart Circ Physiol 299:H975-84. 2010
    ..Considering the safety of curcumin, these studies should facilitate future clinical trials in suppressing hypertrophy in patients with CRF...
  32. ncbi request reprint Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:21-6. 2005
    ..Despite the potential for side effects with CCBs, their potent blood pressure-lowering effect makes them a prerequisite for blood pressure control in many patients...
  33. ncbi request reprint Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations
    Domenic A Sica
    Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertensiion, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:410-6. 2004
    ..This review discusses the physiologic and non-physiologic basis for side effects with ACE inhibition...
  34. ncbi request reprint Controlled-release carvedilol in the treatment of essential hypertension
    Michael A Weber
    Department of Medicine, State University of New York Downstate College of Medicine, New York, New York 10170, USA
    Am J Cardiol 98:32L-38L. 2006
    ..We conclude that carvedilol CR is a very effective antihypertensive agent with clear dose-related peak blood pressure reduction and continuous 24-hour control...
  35. doi request reprint Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment
    Richard A Preston
    Clinical Pharmacology Research Unit, Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, 1500 NW 12th Avenue 15 West, Miami, FL, USA
    Clin Pharmacokinet 52:347-58. 2013
    ..AZL undergoes further metabolism to the major metabolite M-II and minor metabolites. The objective of this study was to determine the effect of renal impairment on the pharmacokinetics of AZL and its major metabolite...
  36. ncbi request reprint The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 5:159-67. 2003
    ..It remains to be determined if this represents a class effect for all angiotensin-converting enzyme inhibitors...
  37. ncbi request reprint Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia Commonwealth University, Richmond 23298, USA
    Curr Opin Nephrol Hypertens 12:123-31. 2003
    ..To characterize the pharmacokinetics and pharmacodynamics of the different calcium-channel blockers...
  38. ncbi request reprint Angiotensin-converting enzyme inhibitor-related angioedema: recognition and treatment
    Maureen P Flattery
    Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Prog Cardiovasc Nurs 22:47-51. 2007
  39. doi request reprint Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system
    Siddhartha S Ghosh
    Division of Nephrology, VCU Medical Center, Virginia Commonwealth University, MCV Station, Box 980160, Richmond, VA, 23298 0160, USA
    Pediatr Nephrol 24:367-77. 2009
    ..Furthermore, AKT (activated via alpha1A receptors), as well as increased alpha1A receptors and their agonist NE, might contribute to the observed hypertrophy...
  40. ncbi request reprint Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Medical College of Virginia of Virginia Commonwealth University, MCBV Station Box 980160, Richmond, VA 23298 0160, USA
    Congest Heart Fail 9:224-9. 2003
    ....
  41. ncbi request reprint Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans
    Jackson T Wright
    Department of Medicine, Division of Hypertension, Case Western Reserve University, Cleveland, Ohio, USA
    Am J Hypertens 17:734-42. 2004
    ....
  42. ncbi request reprint The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    J Renin Angiotensin Aldosterone Syst 3:66-71. 2002
    ..Additional clarifying studies are needed to establish whether specific patient subsets exist that might benefit from such combination therapy...
  43. ncbi request reprint The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
    Domenic A Sica
    Clinical Pharmacology and Hypertension, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, 23298 0160, USA
    J Renin Angiotensin Aldosterone Syst 3:247-54. 2002
    ..These attributes would favour the increased use of ARBs in this population...
  44. ncbi request reprint Use of diuretics in the treatment of heart failure in the elderly
    Domenic A Sica
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
    Clin Geriatr Med 23:107-21. 2007
    ....
  45. ncbi request reprint Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 9:78-86. 2007
    ..Additional outcomes trials, which are currently proceeding to their conclusion, may provide the necessary proof to support an expanded use of these 2 drug classes in combination...
  46. ncbi request reprint EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:91-5. 2004
    ....
  47. ncbi request reprint Centrally acting antihypertensive agents: an update
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 9:399-405. 2007
    ..Escalating doses of drugs in this class often give rise to salt and water retention, in which case diuretic therapy becomes a valuable adjunctive therapy...
  48. ncbi request reprint Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats
    Domenic A Sica
    Medical College of Virginia, Virginia Commonwealth University, Box 980160 MCV Station, Richmond, VA 23298 0160, USA
    Drugs 62:443-62. 2002
    ..If made truly cost-competitive, it will gain an increasing share of the hypertensive market. If not, market forces will relegate it to a secondary role for hypertension treatment...
  49. ncbi request reprint Taking the pressure off type 2 diabetes mellitus: implementing hypertension guidelines
    Rebecca S Grubbs
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
    Prog Cardiovasc Nurs 22:159-65. 2007
    ..Here, the authors review current guidelines for the management of hypertension in patients with type 2 diabetes mellitus and explore ways in which nurse practitioners can improve care for these patients...
  50. ncbi request reprint The risks and benefits of therapy with aldosterone receptor antagonist therapy
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Curr Drug Saf 2:71-7. 2007
    ..As such, steps should be taken to lessen the likelihood of its occurring if therapy is being contemplated with agents in this class...
  51. doi request reprint Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial
    John D Bisognano
    Department of Medicine, Cardiology Division, University of Rochester Medical Center, Rochester, New York, USA
    J Am Coll Cardiol 58:765-73. 2011
    ..We sought to determine the effect of baroreflex activation therapy (BAT) on systolic blood pressure (SBP) in patients with resistant hypertension...
  52. ncbi request reprint Calcium channel blockers: monotherapy and dual therapy considerations in the treatment of hypertension
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
    Am J Cardiovasc Drugs 7:1-3. 2007
    ..provides data from INVEST (INternational VErapamil-Trandolapril STudy), which shows the particular utility of a CCB and ACE inhibitor combination in bringing elderly hypertensive patients with CAD to goal BP when monotherapy..
  53. ncbi request reprint Acute phosphate nephropathy following colonoscopy preparation
    Daniel E Carl
    Department of Medicine, Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Am J Med Sci 334:151-4. 2007
  54. ncbi request reprint Calcium channel blockers: a more expansive treatment role
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:2-4. 2005
  55. ncbi request reprint Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument against
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:117-20; quiz 121-2. 2005
  56. ncbi request reprint ACE inhibitors: over two decades of use
    Domenic A Sica
    Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:531-7. 2005
    ..Dr. Henry R. Black of Rush University Medical Center, Chicago, IL; and Dr. Vito M. Campese of the University of Southern California, Los Angeles, CA...
  57. ncbi request reprint Hyponatremia and heart failure--treatment considerations
    Domenic A Sica
    Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 12:55-60. 2006
    ..Vasopressin receptor antagonists will redefine the treatment of heart failure-related hyponatremia and may possibly evolve as adjunct therapies to loop diuretics in diuretic-resistant patients...
  58. doi request reprint Beyond conventional considerations: newer devices used in blood pressure measurement and management
    Raymond R Townsend
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
    Adv Chronic Kidney Dis 18:48-54. 2011
    ....
  59. ncbi request reprint The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 6:231-41. 2004
    ..Propranolol CR is an effective antihypertensive formulation that may reduce blood pressure during the morning period of maximum cardiovascular risk...
  60. ncbi request reprint Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    Janice G Douglas
    Case Western Reserve University, Department of Medicine, Room W 165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
    Arch Intern Med 163:525-41. 2003
  61. pmc Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss
    Harvey J Sugerman
    Division of General Trauma Surgery, Department of Surgery, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0519, USA
    Ann Surg 237:751-6; discussion 757-8. 2003
    ..To evaluate the preoperative relationships of hypertension and diabetes mellitus in severe obesity and the effects of gastric bypass (GBP)-induced weight loss...
  62. ncbi request reprint Sodium and water retention in heart failure and diuretic therapy: basic mechanisms
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    Cleve Clin J Med 73:S2-7; discussion S30-3. 2006
    ....
  63. ncbi request reprint Pharmacotherapy review: angiotensin-converting enzyme inhibitors
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:485-8. 2005
    ..This article is the first in a series describing important pharmacotherapeutic considerations of the individual drug classes used in the treatment of hypertension...
  64. ncbi request reprint ACE inhibitors and stroke: new considerations
    Domenic A Sica
    Department of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 4:126-9, 133. 2002
  65. ncbi request reprint Obstructive sleep apnea, hypertension, and wakefulness-promoting agents
    Dan Carl
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Curr Hypertens Rep 9:329-31. 2007
  66. ncbi request reprint Hypertension and end-organ disease in African Americans: case presentations
    Domenic A Sica
    Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, 1101 East Marshall Street, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:48-53. 2004
  67. ncbi request reprint Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Congest Heart Fail 9:287-92. 2003
    ..However, the exact role of torsemide in the outpatient management of congestive heart failure remains to be determined...
  68. ncbi request reprint The risks and benefits of aldosterone antagonists
    Domenic A Sica
    Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
    Curr Heart Fail Rep 2:65-71. 2005
    ..Hyperkalemia should be considered as a possibility in any patient receiving these medications and as such is best addressed preemptively...
  69. ncbi request reprint Renal handling of angiotensin receptor blockers: clinical relevance
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA du
    Curr Hypertens Rep 5:337-9. 2003
    ....
  70. doi request reprint Pamidronate-induced kidney injury in a patient with metastatic breast cancer
    Masahiko Nagahama
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    Am J Med Sci 338:225-8. 2009
    ..Renal prognosis is very poor if collapsing FSGS develops. Thus, prevention or early detection rather than effective therapy should be the primary consideration...
  71. ncbi request reprint Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298, USA
    Am J Cardiol 98:1L-4L. 2006
  72. ncbi request reprint Minoxidil: an underused vasodilator for resistant or severe hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 6:283-7. 2004
    ..There is, however, a place for minoxidil in the treatment of resistant hypertension especially in patients with advanced renal disease...
  73. ncbi request reprint Metolazone and its role in edema management
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Congest Heart Fail 9:100-5. 2003
    ..The temptation should be avoided to simply reduce the doses of either metolazone or the loop diuretic as a means to controlling an active diuresis...
  74. ncbi request reprint Nutritional supplementation with Chlorella pyrenoidosa for mild to moderate hypertension
    Randall E Merchant
    Department of Anatomy and Internal Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA 23298 0709, USA
    J Med Food 5:141-52. 2002
    ..The results indicate that, for some subjects with mild to moderate hypertension, a daily dietary supplement of Chlorella reduced or kept stable their SiDBP...
  75. ncbi request reprint Current concepts of pharmacotherapy in hypertension: thiazide-type diuretics: ongoing considerations on mechanism of action
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 6:661-4. 2004
    ..Understanding these issues is important to the effective use of these compounds...
  76. ncbi request reprint Alpha1-adrenergic blockers: current usage considerations
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 7:757-62. 2005
    ....
  77. ncbi request reprint Doxazosin and congestive heart failure
    Domenic A Sica
    Department of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Congest Heart Fail 8:178-84. 2002
    ..A valued member of our therapeutic armamentarium need not be laid entirely to rest; rather, doxazosin should now be viewed as a secondary or tertiary antihypertensive therapy pending a more complete review of the ALLHAT data...
  78. ncbi request reprint Antihypertensive medications and anemia
    Domenic A Sica
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 9:723-7. 2007
    ..A reduction in hemoglobin concentration in a patient who is receiving treatment for hypertension and does not have an obvious source of blood loss should account for potential antihypertensive therapy involvement...
  79. ncbi request reprint Rationale for combination therapy in the treatment of hypertension
    Domenic A Sica
    Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
    J Renin Angiotensin Aldosterone Syst 3:63-5. 2002
    ..Like most matters in the clinical sector the approach to a disease in this case hypertension should remain highly individualised and cognisant of what can be significant cost considerations...
  80. ncbi request reprint Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 1060, USA
    J Clin Hypertens (Greenwich) 4:52-7. 2002
    ..An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy...
  81. ncbi request reprint Baroreflex activation for the treatment of hypertension: principles and practice
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Division of Nephrology, Box 980160, MCV Station, Richmond, VA 23298 0160, USA
    Expert Rev Med Devices 3:595-601. 2006
    ..Clinical trials designed to evaluate the efficacy and safety of this therapy in patients with resistant hypertension are now underway in both Europe and the USA...
  82. ncbi request reprint The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
    J Clin Hypertens (Greenwich) 4:301-5. 2002
    ..The results of this trial are both interesting and relevant to what is an expanding use of angiotensin-receptor blockers in the hypertensive population...
  83. ncbi request reprint Pharmacotherapy review: Angiotensin receptor antagonists
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    J Clin Hypertens (Greenwich) 7:681-4. 2005
    ..Results from a series of outcomes trials increasingly support the use of drugs in this class as cardioprotective and renoprotective agents in patients with heart failure, diabetic nephropathy, and post-myocardial infarction...
  84. ncbi request reprint Hypertension control: still not there-how to select the right add-on therapy to reach goal blood pressures
    Joel M Neutel
    Orange County Research Center, Tustin, CA, USA
    J Clin Hypertens (Greenwich) 9:889-96. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article...
  85. ncbi request reprint Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 8:840-9. 2006
    ..Adverse events, including clinical chemistry values, were similar in the drug-treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period...
  86. ncbi request reprint ALLHAT: is the final answer in?
    Domenic A Sica
    Heart Dis 5:171-5. 2003
  87. ncbi request reprint Hypertension treatment: how important is consistency of effect?
    Domenic A Sica
    Hypertension 50:287-8. 2007
  88. ncbi request reprint Diuretic use in stage 5 chronic kidney disease and end-stage renal disease
    Domenic A Sica
    Curr Opin Nephrol Hypertens 12:483-90. 2003
  89. ncbi request reprint Is there HOPE for ALLHat: similarities and differences
    Domenic A Sica
    Expert Rev Cardiovasc Ther 1:1-2. 2003
  90. ncbi request reprint Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy
    John M Flack
    Wayne State University, University Health Center 2E, 4201 St Antoine, Detroit, MI 48201, USA
    J Clin Hypertens (Greenwich) 7:9-14. 2005
    ....
  91. ncbi request reprint Spironolactone: an old friend rediscovered
    Domenic A Sica
    J Clin Hypertens (Greenwich) 8:467-9. 2006
  92. ncbi request reprint A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly
    Michael A Weber
    Division of Endocrinology, Diabetes, and Hypertension, SUNY Downstate Medical Center, Box 1205, 450 Clarkson Avenue, Brooklyn, NY 11203 2098, USA
    Curr Hypertens Rep 5:319-21. 2003
  93. ncbi request reprint Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren
    Reza Sepehrdad
    Department of Internal Medicine, UC Davis Medical Center, Sacramento, California, USA
    Cardiol Rev 15:242-56. 2007
    ....
  94. ncbi request reprint The use of renin inhibitors in the management of hypertension
    Marvin Moser
    Yale University School of Medicine, New Haven, CT, USA
    J Clin Hypertens (Greenwich) 9:701-5. 2007
  95. ncbi request reprint Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Conn 06030 3940, USA
    Am Heart J 144:657-65. 2002
    ..Therapeutic agents for the treatment of hypertension may differ in their efficacy during the early-morning period, a time when both morbid and mortal cardiovascular events are increased compared with other times of the day...
  96. ncbi request reprint Hypertension treatment guidelines
    Marvin Moser
    Yale University School of Medicine, New Haven, CT, USA
    J Clin Hypertens (Greenwich) 6:452-7. 2004
  97. ncbi request reprint Drospirenone: an antihypertensive in waiting
    Domenic A Sica
    Hypertension 48:205-6. 2006
  98. ncbi request reprint Strategies to improve the cardiovascular risk profile of thiazide-type diuretics as used in the management of hypertension
    Barry L Carter
    University of Iowa, Division of Clinical and Administrative Pharmacy, College of Pharmacy, Department of Family Medicine, Building S 532, Iowa City, Iowa 52242, USA
    Expert Opin Drug Saf 6:583-94. 2007
    ..When these strategies are employed, the adverse effects seen with diuretics can be minimized or negated, and in so doing cardiovascular benefits can be optimized...
  99. ncbi request reprint Endothelin receptor antagonism: what does the future hold?
    Domenic A Sica
    Hypertension 52:460-1. 2008
  100. ncbi request reprint Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study
    Michael Ganz
    Clinical Research Center of Cleveland, CCH Eastern Region, 13951 Terrace Road, Cleveland, OH 44112, USA
    J Clin Hypertens (Greenwich) 7:27-31. 2005
    ..The basis for this more favorable pattern of efficacy and side-effects with controlled-release isradipine, although mechanistically unresolved, may relate to a lesser degree of sympathetic nervous system activation...
  101. ncbi request reprint Fixed-dose combination therapy--is it time for this approach to hypertension and dyslipidemia management?
    Domenic A Sica
    J Clin Hypertens (Greenwich) 6:164-7. 2004